Retrospective 3,433 high-risk patients and matched controls in Canada showing lower mortality with paxlovid use. Patients were divided into four groups based on risk, with improved results as risk increased. Authors did not exclude all contraindicated patients, and do not address confounding by adjuvant treatments, therefore the results are expected to overestimate benefit. (Exclusions are not clear - the paper notes exclusion for severe kidney disease, but this is not in the detailed exclusion list in the appendix, while it is in the inclusion list for CEV2. Contraindications to paxlovid are not mentioned). Confounding may potentially remove all of the benefit seen. The worse results for protection against ER visits is consistent with the confounding being significant - the overestimation of benefit due to confounding based on inclusion of contraindicated patients is expected to increase for more severe outcomes.
Confounding by treatment propensity. This study analyzes a population
where only a fraction of eligible patients received the treatment. Patients
receiving treatment may be more likely to follow other recommendations, more
likely to receive additional care, and more likely to use additional
treatments that are not tracked in the data (e.g., nasal/oral hygiene
c19early.org, c19early.org (B), vitamin D
c19early.org (C), etc.) — either because the physician
recommending paxlovid also recommended them, or
because the patient seeking out paxlovid is more
likely to be familiar with the efficacy of additional treatments and more
likely to take the time to use them.
Malden et al. confirm significant bias in the use of paxlovid, showing that
treated patients are more likely to be from affluent neighborhoods, be more
health-conscious, and have better access to care.
Therefore, these kind of studies may
overestimate the efficacy of treatments.
Confounding by contraindication. Hoertel et al. find that over 50% of patients that died had a contraindication for the use of Paxlovid
Hoertel. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
Black box warning. The FDA notes that
"severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with paxlovid" FDA.
This study is excluded in the after exclusion results of meta
analysis:
only a fraction of eligible patients received treatment and these patients may be more likely to follow other recommendations, receive additional care, and more more likely to use additional untracked treatments such as vitamin D and nasal/oral hygiene; inclusion of contraindicated patients in the control group.
|
risk of death/hospitalization, 29.2% lower, RR 0.71, p = 0.02, treatment 85 of 3,433 (2.5%), control 120 of 3,433 (3.5%), NNT 98, all high-risk patients.
|
|
risk of death/hospitalization, 77.8% lower, RR 0.22, p = 0.06, treatment 2 of 280 (0.7%), control 9 of 280 (3.2%), NNT 40, CEV1.
|
|
risk of death/hospitalization, 48.9% lower, RR 0.51, p = 0.009, treatment 23 of 1,314 (1.8%), control 45 of 1,314 (3.4%), NNT 60, CEV2.
|
|
risk of death/hospitalization, 35.9% lower, RR 0.64, p = 0.10, treatment 25 of 1,050 (2.4%), control 39 of 1,050 (3.7%), NNT 75, CEV3.
|
|
risk of death/hospitalization, 29.6% higher, RR 1.30, p = 0.36, treatment 35 of 789 (4.4%), control 27 of 789 (3.4%), EXEL.
|
|
ER visit, 7.9% lower, RR 0.92, p = 0.37, treatment 232 of 3,280 (7.1%), control 252 of 3,280 (7.7%), NNT 164, all high-risk patients.
|
|
ER visit, 24.1% lower, RR 0.76, p = 0.38, treatment 22 of 264 (8.3%), control 29 of 264 (11.0%), NNT 38, CEV1.
|
|
ER visit, 19.1% lower, RR 0.81, p = 0.13, treatment 93 of 1,259 (7.4%), control 115 of 1,259 (9.1%), NNT 57, CEV2.
|
|
ER visit, 3.2% higher, RR 1.03, p = 0.93, treatment 64 of 1,018 (6.3%), control 62 of 1,018 (6.1%), CEV3.
|
|
ER visit, 15.2% higher, RR 1.15, p = 0.53, treatment 53 of 739 (7.2%), control 46 of 739 (6.2%), EXEL.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Dormuth et al., 2 Oct 2023, retrospective, Canada, peer-reviewed, 5 authors, study period 1 February, 2022 - 3 February, 2023.
Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications
ScD Colin R Dormuth, MPH Jason D Kim, MD Anat Fisher, PhD Jolanta Piszczek, I Fan Kuo
JAMA Network Open, doi:10.1001/jamanetworkopen.2023.36678
IMPORTANCE Postmarket analysis of individuals who receive nirmatrelvir and ritonavir (Paxlovid [Pfizer]) is essential because they differ substantially from individuals included in published clinical trials. OBJECTIVE To examine the association of nirmatrelvir and ritonavir with prevention of death or admission to hospital in individuals with different risks of complications from COVID-19 infection. DESIGN, SETTING, AND PARTICIPANTS This is a cohort study of adult patients in British Columbia, Canada, between February 1, 2022, and February 3, 2023. Patients were eligible if they belonged to 1 of 4 higher-risk groups of individuals who received priority for COVID-19 vaccination. Two groups included clinically extremely vulnerable (CEV) people who were severely (CEV1) or moderately immunocompromised (CEV2). CEV3 individuals were not immunocompromised but had medical conditions associated with a high risk for complications from COVID-19. A fourth expanded eligibility (EXEL) group was added to allow wider access to nirmatrelvir and ritonavir for certain other higherrisk individuals who were not in a CEV group, such as those older than 70 years who were unvaccinated. EXPOSURES Patients with COVID-19 who received nirmatrelvir and ritonavir were matched to patients in the same vulnerability group; who were of the same sex, age, and propensity score for nirmatrelvir and ritonavir treatment; and who were also infected within 1 month of the individual treated with nirmatrelvir and ritonavir.
MAIN OUTCOMES AND MEASURES The primary outcome was death from any cause or emergency hospitalization with COVID-19 within 28 days. RESULTS There were 6866 individuals included in the study, of whom 3888 (56.6%) were female and whose median (IQR) age was 70 (57-80) years. Compared with unexposed controls, treatment with nirmatrelvir and ritonavir was associated with statistically significant relative reductions in the primary outcome in the CEV1 group (560 patients; risk difference [RD], -2.5%, 95% CI, -4.8% to -0.2%) and the CEV2 group (2628 patients; RD, -1.7%; 95% CI, -2.9% to -0.5%). In the CEV3 group, the RD was -1.3%, but the findings were not statistically significant (2100 patients; 95% CI, -2.8% to 0.1%). In the EXEL group, treatment was associated with higher risk of the outcome (RD, 1.0%), but the findings were not statistically significant (1578 patients; 95% CI, -0.9% to 2.9%).
CONCLUSIONS AND RELEVANCE In this cohort study of 6866 individuals in British Columbia, nirmatrelvir and ritonavir treatment was associated with reduced risk of COVID-19 hospitalization or death in CEV individuals, with the greatest benefit observed in severely immunocompromised (continued) Key Points Question What is the association of nirmatrelvir and ritonavir exposure with the risk of death or COVID-19-related hospitalization when accounting for patient vulnerability to complications from COVID-19 infection? Findings In this cohort study of 6866 individuals with COVID-19,..
ARTICLE INFORMATION
References
Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharm Stat,
doi:10.1002/pst.433Bc Covid, Committee, Clinical practice guide for the use of therapeutics in mild-moderate COVID-19
Clinicaltrials, Gov, Evaluation of protease inhibition for covid-19 in standard-risk patients (EPIC-SR)
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Kabore, Laffont, Diop, Tardif, Turgeon et al., Real-world effectiveness of nirmatrelvir/ ritonavir on coronavirus disease 2019 (COVID-19)-associated hospitalization prevention: a population-based cohort study in the province of quebec, canada, Clin Infect Dis,
doi:10.1093/cid/ciad287Latouche, Allignol, Beyersmann, Labopin, Fine, A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions, J Clin Epidemiol,
doi:10.1016/j.jclinepi.2012.09.017Pfizer, Pfizer reports additional data on Paxlovid supporting upcoming new drug application submission to, U.S. FDA
Schneeweiss, Rassen, Glynn, Avorn, Mogun et al., High-dimensional propensity score adjustment in studies of treatment effects using health care claims data, Epidemiology,
doi:10.1097/EDE.0b013e3181a663ccSchwartz, Wang, Tadrous, Population-based evaluation of the effectiveness of nirmatrelvirritonavir for reducing hospital admissions and mortality from COVID-19, CMAJ,
doi:10.1503/cmaj.221608
